Atheroprotective and atheroregressive potential of azapeptide derivatives of GHRP-6 as selective CD36 ligands in apolipoprotein E-deficient mice.

Frégeau G, Sarduy R, Elimam H, Esposito CL, Mellal K, Ménard L, Leitão da Graça SD, Proulx C, Zhang J, Febbraio M, Soto Y, Lubell WD, Ong H, Marleau S

Atherosclerosis6 Jul 2020Cited by 10 (Europe PMC)

PMID32721647DOI10.1016/j.atherosclerosis.2020.06.010PepBankPUB-32721647

Read at source PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

01AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In apoe-deficient mice switched to chow, pooled GHRP‑6 azapeptides decreased aortic arch lesion progression.
In plain wordsIn mice switched to chow, GHRP‑6 azapeptides reduced aortic arch lesion progression.
Peptide
GHRP-6
Outcome
DecreaseAortic arch lesion progression on chow
Study
mousen: not reported in source
apoe-deficient mice
Outcome group
Atherosclerotic lesions · Cardiovascular
Source sentences
Summary
Azapeptides decreased lesion progression in the aortic arch and reduced aortic sinus lesion areas below pre-existing lesions levels in apoe^-/- mice which were switched to chow diet.
1 context sentence(design, population, supporting numbers)
Summary · context
Azapeptide analogs of growth hormone-releasing peptide-6 (GHRP-6) have been developed as selective CD36 ligands and evaluated for their anti-atherosclerotic properties in apoe^-/- mice.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-3272164701
02AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In apoe-deficient mice switched to chow, pooled GHRP‑6 azapeptides reduced aortic sinus lesion areas below pre-existing levels.
In plain wordsIn mice switched to chow, GHRP‑6 azapeptides reduced aortic sinus lesions below pre-existing levels.
Peptide
GHRP-6
Outcome
DecreaseAortic sinus lesion area on chow
Study
mousen: not reported in source
apoe-deficient mice
Comparator
Pre-existing lesions
Outcome group
Atherosclerotic lesions · Cardiovascular
Source sentences
Summary
Azapeptides decreased lesion progression in the aortic arch and reduced aortic sinus lesion areas below pre-existing lesions levels in apoe^-/- mice which were switched to chow diet.
1 context sentence(design, population, supporting numbers)
Summary · context
Azapeptide analogs of growth hormone-releasing peptide-6 (GHRP-6) have been developed as selective CD36 ligands and evaluated for their anti-atherosclerotic properties in apoe^-/- mice.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-3272164702
03AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In mice maintained on HFHC, pooled GHRP‑6 azapeptides reduced aortic vessel lesion progression.
In plain wordsIn mice maintained on HFHC, GHRP‑6 azapeptides reduced aortic vessel lesion progression.
Peptide
GHRP-6
Outcome
DecreaseAortic vessel lesion progression on HFHC
Study
mousen: not reported in source
apoe-deficient mice
Outcome group
Atherosclerotic lesions · Cardiovascular
Source sentences
Summary
In mice fed a HFHC throughout the study, azapeptides reduced lesion progression in the aortic vessel and sinus.
1 context sentence(design, population, supporting numbers)
Summary · context
Azapeptide analogs of growth hormone-releasing peptide-6 (GHRP-6) have been developed as selective CD36 ligands and evaluated for their anti-atherosclerotic properties in apoe^-/- mice.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-3272164703
04AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In mice maintained on HFHC, pooled GHRP‑6 azapeptides reduced aortic sinus lesion progression.
In plain wordsIn mice maintained on HFHC, GHRP‑6 azapeptides reduced aortic sinus lesion progression.
Peptide
GHRP-6
Outcome
DecreaseAortic sinus lesion progression on HFHC
Study
mousen: not reported in source
apoe-deficient mice
Outcome group
Atherosclerotic lesions · Cardiovascular
Source sentences
Summary
In mice fed a HFHC throughout the study, azapeptides reduced lesion progression in the aortic vessel and sinus.
1 context sentence(design, population, supporting numbers)
Summary · context
Azapeptide analogs of growth hormone-releasing peptide-6 (GHRP-6) have been developed as selective CD36 ligands and evaluated for their anti-atherosclerotic properties in apoe^-/- mice.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-3272164704
05AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism
In atherosclerotic mice, pooled GHRP‑6 azapeptide effects were associated with a reduced lesional iNOS-positive/CD206-positive macrophage ratio.
In plain wordsIn mice, GHRP‑6 azapeptide effects were linked to a lower ratio of inflammatory to M2-like macrophages in lesions.
Peptide
GHRP-6
Outcome
DecreaseLesional iNOS-positive/CD206-positive macrophage ratio
Study
mousen: not reported in source
apoe-deficient mice
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
The anti-atherosclerotic effect of azapeptides was associated with a reduced ratio of iNOS⁺/CD206⁺ macrophages within lesions, and lowered plasma inflammatory cytokine levels.
1 context sentence(design, population, supporting numbers)
Summary · context
Azapeptide analogs of growth hormone-releasing peptide-6 (GHRP-6) have been developed as selective CD36 ligands and evaluated for their anti-atherosclerotic properties in apoe^-/- mice.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-3272164705
06AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In atherosclerotic mice, pooled GHRP‑6 azapeptide effects were associated with lower plasma inflammatory cytokine levels.
In plain wordsIn mice, GHRP‑6 azapeptide effects were linked to lower blood inflammatory cytokine levels.
Peptide
GHRP-6
Outcome
DecreasePlasma inflammatory cytokines
Study
mousen: not reported in source
apoe-deficient mice
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
The anti-atherosclerotic effect of azapeptides was associated with a reduced ratio of iNOS⁺/CD206⁺ macrophages within lesions, and lowered plasma inflammatory cytokine levels.
1 context sentence(design, population, supporting numbers)
Summary · context
Azapeptide analogs of growth hormone-releasing peptide-6 (GHRP-6) have been developed as selective CD36 ligands and evaluated for their anti-atherosclerotic properties in apoe^-/- mice.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-3272164706
07AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism
In azapeptide-treated mice, monocytes showed altered mitochondrial oxygen consumption consistent with an M2-like phenotype.
In plain wordsIn mice treated with GHRP‑6 azapeptides, monocyte oxygen use changed in a pattern consistent with M2-like cells.
Peptide
GHRP-6
Outcome
Direction not reportedMonocyte mitochondrial oxygen consumption
Study
mousen: not reported in source
apoe-deficient mice
Outcome group
Mitochondrial function · Cardiovascular
Source sentences
Summary
Monocytes from azapeptide-treated mice showed altered mitochondrial oxygen consumption rates, consistent with an M2-like phenotype.
1 context sentence(design, population, supporting numbers)
Summary · context
Azapeptide analogs of growth hormone-releasing peptide-6 (GHRP-6) have been developed as selective CD36 ligands and evaluated for their anti-atherosclerotic properties in apoe^-/- mice.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-3272164707
08AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism
In apoe/cd36 double-deficient mice, the effects of pooled GHRP‑6 azapeptides were not observed.
In plain wordsIn mice lacking apoe and cd36, GHRP‑6 azapeptide effects were absent.
Peptide
GHRP-6
Outcome
No significant changeCD36 dependence of azapeptide effects
Study
mousen: not reported in source
apoe/cd36 double-deficient mice
Outcome group
Receptor activity and mechanism · Cardiovascular
Source sentences
Summary
These effects were dependent on CD36, and not observed in apoe^-/-cd36^-/- mice.
1 context sentence(design, population, supporting numbers)
Summary · context
Azapeptide analogs of growth hormone-releasing peptide-6 (GHRP-6) have been developed as selective CD36 ligands and evaluated for their anti-atherosclerotic properties in apoe^-/- mice.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-3272164708

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.